2025-09-14 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc (HIMS) based on the provided data, presented in an organized report format.

**Report: Hims & Hers Health Inc (HIMS) Analysis**

**1. Executive Summary**

Hims & Hers Health Inc (HIMS) is a telehealth company that offers personalized health and wellness solutions directly to consumers.  HIMS has significantly outperformed the S&P 500 recently, but faces mixed analyst opinions and an expected underperformance against the S&P 500 in the long term. Recent news suggests growth in hormone health services and positive market sentiment.

**2. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (HIMS):** 212.78%
*   **Cumulative Return (VOO):** 74.55%
*   **Absolute Divergence:** 271.5
*   **Relative Divergence:** 62.4 (Indicates HIMS is positioned high relative to its historical performance compared to VOO.)

**Analysis:** HIMS has significantly outperformed the S&P 500. The relative divergence suggests that HIMS's current outperformance is high compared to its historical patterns.

**3. Alpha, Beta, and Risk Metrics**

| Year       | CAGR    | MDD    | Alpha  | Beta | Cap(B) |
|------------|---------|--------|--------|------|--------|
| 2019-2021  | -46.0%  | 51.0%  | -85.0% | 0.1  | 1.5    |
| 2020-2022  | -15.0%  | 72.1%  | -21.0% | 0.0  | 1.4    |
| 2021-2023  | -51.0%  | 72.1%  | -71.0% | -0.2  | 2.0    |
| 2022-2024  | 127.0%  | 78.4%  | 100.0% | -0.3  | 5.5    |
| 2023-2025  | 208.0%  | 80.7%  | 154.0% | -0.2  | 12.5   |

**Analysis:**
*   **CAGR:** Shows strong recent growth (2023-2025), but significant past volatility.
*   **MDD:** High Maximum Drawdown values indicate substantial risk.
*   **Alpha:**  Recent years show positive alpha, indicating outperformance relative to its risk. Alpha is the return on an investment over and above a benchmark index.
*   **Beta:**  Beta values generally show high volatility compared to the market. Beta is a measure of the volatility of a stock relative to the overall market. A beta greater than 1 indicates that the stock is more volatile than the market, while a beta less than 1 indicates that the stock is less volatile than the market.
*   **Cap(B):** Market capitalization has increased significantly in recent years.

**4. Recent Price Action**

*   **Current Price:** 55.5
*   **Previous Close:** 51.76
*   **Change:** 7.23 (Significant positive change)
*   **5-Day Moving Average:** 50.494
*   **20-Day Moving Average:** 46.125
*   **60-Day Moving Average:** 50.246

**Analysis:** The current price is above all moving averages, indicating a short-term bullish trend. The large change from the previous close suggests a strong upward price movement.

**5. Market Risk Indicators & Signals**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 71.73 (Overbought)
*   **PPO:** 2.72
*   **Hybrid Signal:**  cash_0%_Buy 90% of cash
*   **Delta_Previous_Relative_Divergence:** 4.2 (+) (Short-term increase)
*   **Expected Return (%):** -17.7% (Long-term underperformance vs. S&P 500)

**Analysis:**
*   **MRI:** Indicates low market risk.
*   **RSI:** Suggests the stock is currently overbought and may be due for a correction.
*   **PPO:** Positive PPO suggests a short-term uptrend.
*   **Hybrid Signal:** The hybrid signal suggests a buying opportunity, potentially capitalizing on current momentum.
*   **Delta_Previous_Relative_Divergence:** Confirms recent positive momentum.
*   **Expected Return:** Is forecasting underperformance over a long-term horizon

**6. Recent News & Events**

*   **Focus on Hormone Health:**  Expanding into hormone health may drive future growth.
*   **Positive Stock Performance:**  Multiple articles highlight recent surges in HIMS stock.
*   **Growth Stock Recognition:**  HIMS is being recognized as a leading growth stock.
*   **Testosterone Foray:**  Entry into testosterone market is driving positive market reaction.

**Analysis:**  Recent news is overwhelmingly positive, focusing on growth initiatives, market recognition, and stock performance. The market is reacting favorably to these developments.

**7. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.75 (~Hold)
*   **Number of Opinions:** 11
*   **Target Price (avg/high/low):** 49.45 / 85.00 / 28.00
*   **Recent Rating Changes:** No significant changes reported.

**Analysis:**  Analyst opinions are mixed, with a consensus rating of "Hold." The average target price is below the current price, suggesting limited upside potential according to analysts.

**8. Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2024-08-05 | 0.06 | 0.32 B$   |
| 2025-08-04 | 0.06 | 0.32 B$   |

**Analysis:**

* EPS and revenue have shown some inconsistency. The most recent EPS data is not available from the information provided.

**9. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $0.54B     | 76.39%        |
| 2025-03-31   | $0.59B     | 73.50%        |
| 2024-12-31   | $0.48B     | 76.81%        |
| 2024-09-30   | $0.40B     | 79.16%        |
| 2024-06-30   | $0.32B     | 81.30%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-06-30   | $0.56B     | 7.55%     |
| 2025-03-31   | $0.55B     | 9.01%     |
| 2024-12-31   | $0.48B     | 5.46%     |
| 2024-09-30   | $0.44B     | 17.18%    |
| 2024-06-30   | $0.36B     | 3.67%     |

**Analysis:**
*   **Revenue:**  Generally increasing, with some fluctuations.
*   **Profit Margin:** Remains relatively high, but with a slight downward trend recently.
*   **Equity:** Increasing, indicating strengthening financial position.
*   **ROE:** Highly variable, suggesting inconsistent profitability on equity.

**10. Overall Assessment & Conclusion**

Hims & Hers Health (HIMS) presents a mixed investment picture.

*   **Positive Factors:** Strong recent stock performance, positive news flow related to growth initiatives, and a low market risk indicator.
*   **Negative Factors:**  Overbought RSI, mixed analyst opinions, high volatility, and a negative long-term expected return relative to the S&P 500.

**Overall, the stock appears to have strong short-term momentum, but potential investors should be aware of the high volatility and mixed long-term outlook.**  A cautious approach is advised, considering the potential for a price correction and the analyst consensus of "Hold." Further investigation into the long-term growth strategy and profitability sustainability is warranted.
